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and IL-4 production by resting and mitogen-
activated T cells of luteal bitches
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Background: Aglepristone (RU534) is an antiprogestin used for pregnancy termination, parturition induction and
conservative pyometra treatment in bitches. Its molecular structure is similar to mifepristone, an antiprogestin used
in human medicine. Mifepristone has been shown to suppress proliferation and cytokine production by T cells,
whereas the effect of aglepristone on T cell function remains elusive. The purpose of this project was to investigate
the in vitro influence of RU534 on IFN-γ and IL-4 synthesis by peripheral blood T cells isolated from healthy bitches
(N = 16) in luteal phase. The peripheral blood mononuclear cells (PBMCs) were incubated with three different
dosages of aglepristone, or dimethyl sulfoxide (DMSO), with or without mitogen. The production of cytokines by
resting or mitogen-activated T cells was determined by intercellular staining and flow cytometry analysis or ELISA
assay, respectively.
Results: Our results showed no statistically significant differences in the percentage of IFN-γ and IL-4-synthesizing
CD4+ or CD8+ resting T cells between untreated and aglepristone-treated cells at 24 and 48 hours post treatment.
Moreover, mitogen-activated PBMCs treated with RU534 displayed similar concentration of IFN-γ and IL-4 in culture
supernatants to those observed in mitogen-activated DMSO-treated PBMCs. Presented results indicate that
administration of aglepristone for 48 hours has no influence on IFN-γ and IL-4 synthesis by resting and mitogen-
activated T cells isolated from diestral bitches.
Conclusions: We conclude that antiprogestins may differentially affect T cell function depending on the animal
species in which they are applied.
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Aglepristone (RU534) is the only registered antiprogestin
in veterinary medicine. This nuclear progesterone receptor
(nPR) antagonist has a higher affinity for nPR than proges-
terone itself [1]. This medication was initially used for
pregnancy termination. Currently, aglepristone is used for
induction of parturition and in the treatment of canine and
feline pyometra [2]. Recently, there were also attempts to
use aglepristone in the therapy of progesterone-dependent
disorders in dogs, such as: growth hormone excess [3], va-
ginal fibroma [4] and mammary gland carcinoma [5].* Correspondence: piotr_jurka@sggw.pl
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reproduction in any medium, provided the orAglepristone is known to block the progesterone action
on target cell receptors. In bitches aglepristone abolishes
the inhibitory effect of progesterone on the uterine myo-
metrium. Studies conducted in vitro have demonstrated
that aglepristone enhances contractile response of myo-
metrial fibers to oxytocin and prostaglandin PGF2alpha
during metestrus [6]. The administration of aglepristone
during the early luteal phase in healthy non-pregnant
bitches shortened the interestrous interval suggesting that
aglepristone influences the hypothalamic-pituitary-ovarian
axis [7].
Aglepristone is a very effective drug in conservative
treatment of canine pyometra. It is thought that pyome-
tra is linked to a hormonal imbalance and progesterone
dominance in luteal phase which, in turn, suppresses the
local innate immunity and favours bacterial colonizationd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the pathogenesis of pyometra, pharmacological blockade
of nPR by aglepristone may lead to fast recovery [9]. In
vivo studies have shown that bitches with pyometra 14
days post treatment with aglepristone showed a de-
creased number of monocytes and granulocytes com-
pared to reference values [10]. Furthermore, studies by
Fieni and collogues [11] have indicated that inhibition of
nPR by aglepristone in bitches with pyometra signifi-
cantly reduced the leukocyte count and plasma pro-
gesterone concentrations over the course of treatment.
After 48 hours of aglepristone administration bitches
with closed pyometra showed cervical opening with sub-
sequent evacuation of purulent discharge from uterus
and improvement in the animal’s condition [11]. How-
ever, the exact mechanism of aglepristone action in the
treatment of pyometra remains unknown. We can only
suppose that aglepristone may have an influence on rever-
sion of immune suppression induced by progesterone.
Much of our current understanding of the potential ef-
fect of aglepristone on canine immune cells comes from
studies of the mifepristone (RU486), the first synthesized
antiprogestin used in human medicine. Mifepristone is
now classified as a selective progesterone-receptor modu-
lator (SPRM) due to its mixed antagonist/agonist action
on PR. Additionally, it is an antagonist/agonist of the
glucocorticoid receptor (GR) [12]. Mifepristone has a very
similar molecular structure to aglepristone [1]. In humans
mifepristone is used for early termination of pregnancy
and in the therapy of progesterone-dependent tumors
[13]. Mifepristone was successfully used for pregnancy ter-
mination in dogs [14]. It also exerts an anti-glucocorticoid
effect in this species. In dogs RU486 alters adrenal func-
tion by inducing an increase in plasma adrenocorticotro-
pic hormone (ACTH) and cortisol concentrations [15,16].
It has been demonstrated that mifepristone suppressed
proliferation and downregulated the interleukin-2 receptor
(IL-2R) mRNA in human lymphocytes. Moreover, mife-
pristone acted as a GR agonist and inhibited secretion of
IL-2 and IL-3 by phytohemagglutinin (PHA)-activated
normal human peripheral blood lymphocytes (NPBL) [17].
Mifepriston enhanced cytotoxicity of peripheral blood NK
cells isolated from woman in implantation phase [18] and
uterine NK (uNK) cells isolated at the window of implant-
ation [19]. Additionally, RU-486 inhibited suppressive ef-
fect of P4 on IFN-γ mRNA expression in uNK cells
stimulated with CpG and IL-12. The same effect was ob-
served in murine splenic NK cells isolated in diestrus [20].
Bitches in luteal phase are under immunosuppression.
PBMCs isolated form bitches in diestrus showed de-
creased proliferation in response to lipopolysaccharide
(LPS) derived from E. coli and PHA compared to cells
isolated in other phases of estrus cycle [21,22]. Data con-
cerning pyometra treatment and mifepristone actionsuggest that aglepristone may have an influence on ca-
nine immune cells.
For that reason, the aim of the present study was to
investigate the in vitro effect of aglepristone on cytokine
synthesis by resting and mitogen-activated T cells iso-
lated from bitches in luteal phase.
Methods
Animals
In the study 16 healthy bitches at different age (9
months - 7 years, average 2 years) and different breeds
were used. All bitches were in luteal phase (2 weeks after
estrus) confirmed by anamnesis, clinical examination,
cytology and peripheral blood progesterone concen-
tration assay. Investigations were carried out after the
obtaining an agreement from III-rd Local Animal Ex-
perimentation Committee at the Warsaw University of
Life Sciences number lke 72/2009 and an agreement of
the Dean of the Faculty of Veterinary Medicine, Warsaw
University of Life Sciences number 1/2009. Such permis-
sions are necessary before the receipt of the grant from
the National Science Centre, Poland and are in accord-
ance with the Law of United Europe.
Blood samples and hormonal profiles
Blood samples were collected from the supraradial vein
every 7 days starting from the 1st day after estrus (con-
firmed by hormonal examination and vaginal cytology).
Blood for in vitro investigation was taken on day 14 of the
luteal phase. Measurements of progesterone concentra-
tions were performed using commercial immunoenzymatic
tests for quantitative determination of P4. Measurement of
optical density was taken with a Pointe 2000 apparatus
(Pointe Scientific, Poland). Each analysis was performed
two times in each series. Efficiency of extraction oscillated
between 92% and 99%. Assay sensitivity and intra-series
errors were 0.05 ng/ml (0.8 nmol/l) and 8.0% respectively
for P4.
Isolation of PBMCs
Before isolation of PBMCs, EDTA peripheral blood was
centrifuged at 250 × g for 20 min to obtain plasma
which was collected and stored on ice until use. PBMCs
were isolated from the remaining EDTA peripheral
blood diluted twofold with two-times concentrated
RPMI 1640 medium (Gibco, USA) using 50% (v/v)
Percoll (Sigma–Aldrich) gradient with centrifugation at
400 × g for 30 min. Collected PBMCs were washed twice
with RMPI 1640 and red blood cells were then lysed in
NH4Cl/Tris buffer for 10 min on ice. After washing,
PBMCs were resuspended in culture medium RMPI
1640 supplemented with 10% (v/v) fetal bovine serum
(FBS, HyClone, USA) and 1% (v/v) antibiotic–antimycotic
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amfotericin) (Sigma–Aldrich) at 5 × 106/ml.
PBMCs treatment and stimulation
For enumeration of cytokine-synthesizing T cells by flow
cytometry, PBMCs were placed at 5 × 105/well in a flat-
bottom 96-well plate and treated with increased concen-
trations of aglepristone (Alizine, Virbac, France) diluted
in dimethyl sulfoxide (DMSO) i.e. 30, 300 and 3000 ng
or with DMSO alone, as a negative control. After 24
and 48 h of treatment, PBMCs were restimulated using
50 ng/ml of phorbol 12-myristate 13-acetate (PMA,
Sigma–Aldrich) and 4 μg/ml of ionomycin (Sigma–Aldrich)
in the presence of 15 μg/ml brefeldin A (BD Biosciences,
USA) for 4 h at 37°C in 5% CO2 [23].
For measurement of cytokine concentration by ELISA,
PBMCs seeded in a flat-bottom 96-well plate were treated
with DMSO or 30, 300 and 3000 ng of aglepristone to-
gether with mitogens: concanavalin A (Con A, 1 μg/ml;
Sigma-Aldrich) or PHA (10 μg/ml; Sigma-Aldrich). After
24 and 48 h supernatants were collected and stored
at −20°C for further experiments.
Surface and intracellular staining
After restimulation PBMCs were washed in phosphate
buffered saline (PBS) and blocked for nonspecific bind-
ing in 30% (v/v) FBS in PBS for 30 min on ice. Surface
staining was performed using monoclonal antibodies
(mAb) conjugated with fluorescein isothiocyanate (FITC)
against canine CD4 or canine CD8 (both from AbD
Serotec, UK) surface molecules. Intracellular staining
was then performed using Cytoix/Cytoperm kit (BD Bio-
sciences) in accordance with the manufacturer’s instruc-
tions. Briefly, cells were fixed and permeabilized with
Cytoix/Cytoperm solution for 25 min on ice followed by
washing in Perm/Wash solution. Next, cells were stained
for 30 min on ice with the respective phycoerythrin
(PE)-labeled mAb directed against bovine IFN-γ or bo-
vine IL-4 (both from AbD Serotec). Cross-reactivity of
these mAbs with canine cytokines was previously de-
scribed [24]. After washing, PBMCs were fixed in 2%
paraformaldehyde (PFA, Sigma–Aldrich) in PBS and an-
alyzed by flow cytometry within 24 h. In all experiments
negative controls were run with each set of samples.
Flow cytometry analysis
Analysis of intracellular cytokine staining was performed
using FACSCalibur flow cytometer equipped with the
CellQuest software (Becton Dickinson, USA). Results
were determined as a percentage of CD4+ or CD8+ T
cells synthesizing cytokine, and as mean fluorescent in-
tensity (MFI) of a cytokine-positive CD4+ or CD8+ T cell
subpopulation. Data from 2 × 104 events were acquired
for each sample. Lymphocytes were gated by the regiondetermined by forward (FSC) and side (SSC) scatter
characteristics.
ELISA assay
ELISA for canine IFN-γ and IL-4 was performed using
kits purchased from R&D Systems (USA) and EIAab
(China), respectively, according to the manufacturer’s in-
structions. Kits had a detection sensitivity of 60 pg/ml
and 7, 8 pg/ml for IFN-γ and IL-4, respectively.
Data analysis and statistics
The percentage of cytokine-producing T cells and the MFI
of cytokine-positive T cells-treated with aglepristone were
presented relative to control values. The concentrations of
cytokines in culture supernatants of mitogen-stimulated
PDMC-treated with aglepristone were also presented rela-
tive to control values. All data were expressed as mean ±
standard deviation (SD). Differences between aglepristone-
treated and untreated control PBMCs at indicated time
points were calculated using the Student’s t-test for paired
samples (in case of normal data distribution) or nonpara-
metric Wilcoxon signed rank test (STATISTICA 6.0 soft-
ware, StatSoft). Statistical significance was determined at
P ≤ 0.05.
Results
Synthesis of IFN-γ and IL-4 by CD4+ and CD8+ T cells-
treated with aglepristone
We examined the in vitro effect of aglepristone on the
synthesis of IFN-γ and IL-4 by canine CD4+ and CD8+
T cells isolated from peripheral blood of bitches in the lu-
teal phase. The concentration of progesterone in blood of
the studied bitches was high and ranged from 25,3 ng/ml
to 36,7 ng/ml (fairly 30,9 ± 6,3 ng/ml). To achieve synthe-
sis of cytokines, T cells were restimulated in vitro with
ionomycin and PMA for 4 h, which was chosen to be an
optimal time for restimulation (data not shown). For all
the experiments, the percentage of cytokine-producing T
cells and MFI of cytokine-positive T cells treated with
aglepristone were normalized to the DMSO-treated con-
trol cells. At first, we assessed the in vitro influence of
aglepristone on the percentage of T cell subsets (CD4+
and CD8+). Our results demonstrated no effect of agle-
pristone on the CD4+/CD8+ T cells ratio (data not shown)
after 24 and 48 h of treatment.
Representative dot blots showing synthesis of IFN-γ by
CD4+ and CD8+ T cells isolated from diestral bitches
and in vitro treated with DMSO (control) or 30, 300 and
3000 ng/ml of aglepristone, are presented on Figure 1.
The percentage of CD4+ T cells-synthesizing IFN-γ
ranged from 6.0% to 18.1% and 4.7% to 18.6% in control
cells, 5.2% to 27.7% and 4.2% to 24.0% in cells treated
with 30 ng/ml of aglepristone, 4.3% to 22.1% and 6.9%
to 20.5% in cells treated with 300 ng/ml of aglepristone,
Figure 1 Representative dot plots show synthesis of IFN-γ by CD4+ (A) and CD8+ (B) T cells isolated from diestral bitches and treated
for 24 and 48 h with DMSO (control) or 30, 300 and 3000 ng/ml of aglepristone. Numbers within quadrants represent the percentage of
positive cells for a given marker within the gate for lymphocytes. MFI of IFN-γ in T cell subsets is shown within upper right quadrants.
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3000 ng/ml of aglepristone, at 24 and 48 h of incubation,
respectively. Our results showed no differences in the
percentage of CD4+ T cells-synthesizing IFN-γ between
control and studied groups (Figure 2A). Moreover, flow
cytometric analysis revealed no effect of aglepristone on
MFI of IFN-γ produced by CD4+ T cells (Figure 2B).
The percentage of CD8+ T cells-synthesizing IFN-γ in
control and aglepristone-treated groups ranged from
15% to around 60% at 24 and 48 h of incubation. Simi-
larly to CD4+ T cells, CD8+ T cells synthesized IFN-γ at
similar levels in the control and aglepristone-treated
groups (Figure 2).
The percentage of both CD4+ and CD8+ T cells-
synthesizing IL-4 ranged from around 1% to around 4%
in control group and groups treated with different dos-
ages of aglepristone (Figure 3). Our results indicated
no statistically significant changes in the percentage of
IL-4-synthesizing CD4+ and CD8+ T cells in group
treated with aglepristone compared to control group
(Figure 4A). Moreover, in both T cell subsets no statis-
tically significant changes in MFI of IL-4 expression
were observed between control and studied groups
(Figure 4B).No effect of aglepristone on IFN-γ and IL-4 production by
mitogen-activated PBMCs
Next, we examined whether aglepristone influences the
production of cytokines by mitogen-activated PBMCs.
Because ConA and PHA was shown to stimulate T but
not B cells [25], we can assume that most IFN-γ and IL-
4 in culture supernatant derived from activated T cells.
PBMCs stimulation with ConA or PHA significantly
increased IFN-γ and IL-4 production compared to un-
stimulated cells (data not presented). Moreover, ConA-
stimulated PBMC produced significantly (P ≤ 0.01) more
IFN-γ than PHA-stimulated cells (Figure 5), however the
proliferation activity was higher in the latter cells (data
not presented).
Our results showed that aglepristone has no effect on
IFN-γ and IL-4 production by canine PBMCs, induced
neither by ConA nor PHA (Figure 6). The level of IFN-γ
and IL-4 in culture supernatants of aglepristone-treated
cells was comparable with control cells, treated only
with DMSO.
Discussion
This is the first study on the in vitro influence of agle-
pristone on IFN-γ and IL-4 synthesis by resting CD4+
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Figure 2 The percentage of IFN-γ-synthesizing T cell subsets
(A) and the MFI of IFN-γ-positive T cell subsets (B) treated for
24 and 48 h with 30, 300 and 3000 ng/ml of aglepristone.
All data are presented relative to control values (line). Each point
represents an individual dog (n = 7–9), with the bar indicating the
mean. *P < 0.05, ** P < 0.01.
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isolated from luteal bitches. The concentration of P4 in
the luteal phase of bitches is always very high and sup-
presses the function of the immune system cells [2].
The results of our study showed that there are no
statistically significant differences in the percentage of
CD4+ and CD8+ T cells-synthesizing IFN-γ or IL-4 be-
tween the control group and groups treated with different
dosages of aglepristone. Moreover, we did not observe the
dose-effect relationship between aglepristone exposure and
the production of cytokines by T cell subsets. Based on our
results we can conclude that aglepristone has no in vitro ef-
fect on resting CD4+ and CD8+ T cell differentiation toward
T helper 1 (Th1) or Th2 and T cytotoxic 1 (Tc1) or Tc2
phenotype, respectively.
The second analyzed parameter was MFI of cytokines
synthesized by T lymphocyte subsets. Statistical analysis
did not reveal any significant differences in IFN-γ or IL-
4 synthesis by resting Th1 or Tc1 and Th2 or Tc2 cells,
respectively, treated with aglepristone compared to un-
treated control cells. Moreover, aglepristone did notsuppress mitogen-derived production of IFN-γ and IL-4
by PBMCs isolated from bitches in luteal phase. Our re-
sults indicate that aglepristone has no suppressive effect
on IFN-γ and IL-4 synthesis by resting and mitogen-
activated T cells.
It is known that mifepristone, an analogue of aglepris-
tone, inhibits many human T cell function. Mifepristone
alone or synergistically with progesterone was shown to
inhibit a PHA-induced proliferation of human T cells
[26]. It also suppressed a production of IL-3 and IL-2 by
those cells [17]. It is thought that its suppressive effect
on human T cell function is mediated by agonistic action
on GR [27]. Moreover, mifepristone suppressed in a
dose-dependent manner a rapid non-genomic responses
caused by progesterone, such as increased intracellular
calcium (Ca2+) and decreased intracellular pH in human
T cells [26]. No effect of aglepristone on the synthesis of
IFN-γ and IL-4 may suggest that aglepristone at a con-
centration < 3 μg/ml does not affect the activation of
canine T lymphocytes. The maximal concentration of
aglepristone after 2 injections of 10 mg/kg/day at a 24 h
interval is achieved after 2.5 days and reached 280 ng/ml.
It cannot be excluded that aglepristone has no influence
on T cell cytokine synthesis in in vivo conditions. More-
over, it cannot be excluded that aglepristone performs a
modulatory effect on T cells activation/function at a higher
concentration (> 3 μg/ml). Mifepristone was shown to
have a significant dose dependent inhibitory influence on
proliferation of PHA-stimulated human T cells at 5 μM
and above [26]. The effect of mifepristone on canine T cell
function has not been investigated to-date, thus it is not
known whether a potential mechanism of inhibition of T
lymphocyte properties by RU486 is similar in human and
canine T cells. Additionally, we cannot exclude that agle-
pristone is not an agonist of canine GR or has low affinity
to GR. However, it is still possible that aglepristone affects
the production of other cytokines by T cells and/or their
proliferation. These matters need further examination.
We also have to remember about potential differences
between aglepristone and mifepristone action. Mifepris-
tone is a selective receptor modulator and its action on
target cells has not been clearly defined. It shows mixed
agonist/antagonist affinity to both GR and PR. The type
of mifepristone action depends on the cell type [28], re-
ceptors level [29], promoter context [30] and level of
modulatory molecules in cell environment [28]. The ag-
onistic action of mifepristone on GR has been studied in
different cells lines transfected with pMTVCAT, where
acetyltransferase (CAT) gene was under regulation of
glucocorticoid-inducible promoter. The agonist activity
of mifepristone depended on cell line and GR expres-
sion. Expression of glucocorticoid related genes after
mifepristone treatment increased proportionally to GR
level in those cells. Agonistic effect of mifepristone was
Figure 3 Representative dot plots show synthesis of IL-4 by CD4+ (A) and CD8+ (B) T cells isolated form bitches in luteal phase and
treated for 24 and 48 h with DMSO (control) or 30, 300 and 3000 ng/ml of aglepristone. Numbers within quadrants represent the
percentage of positive cells for a given marker within the gate for lymphocytes. MFI of IL-4 in T cell subsets is shown within upper
right quadrants.
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Liu and coworkers [28] demonstrated that mifepristone
has different influence on transcription activity on P4 re-
lated genes in different cell types. It correlates with the
ratio of endogenous coactivators/corepressors in those
cells [28]. The aglepristone action on canine T cells is
hard to define based on mifepristone data, because of
many factors involved in its interaction with target cells.
For that reason, future studies are needed to determine
factors influencing the aglepristone action on target cells
including affinity to GR, promoter context, type of cells
and presence of modulatory molecules in the cellular
environment.
The exact mechanism of aglepristone action is not
known. There are two types of antiprogestins. Type II
refers to molecules that bind to the receptor and pro-
mote its binding to HREs (hormone response elements)
of target genes. Binding of antiprogestin-receptor com-
plex to HREs does not activate transcription, because of
inefficient conformation charges of the receptor [29].
Type I antiprogestins bind to the receptor but do
not promote its binding to DNA. This mechanism of
action is limited to passive blockage of the receptor.Mifepristone is type II antiprogestin [31]. In contrast to
mifepristone, onapristone – type I antiprogestin, has no
influence on transcription of progesterone related genes.
Onapristone is considered to be pure antagonist of PR.
It shows only minimal affinity to GR [12], however
in vivo studies in rats may suggest its potential agonistic
and antagonistic action on GR [32].
It is not known whether aglepristone is a type I or type II
antiprogestin. Onapristone differs from mifepristone not
only in C17 chain structure but also in stereochemical con-
formation at C18 [33]. It is thought that the affinity to GR
is related to the bend structure at A/B ring junction of ster-
oid skeleton [34]. Aglepristone has the same stereochemical
structure as mifepristone. The only dissimilarity between
these two compounds is C17 structure. Aglepristone has 1-
propenyl side chain at the 17α position, whereas mifepris-
tone has a 17α-1-propinyl group [1]. We cannot exclude
that even slight differences in this chain structure may im-
pact the conformation of the whole molecule. The mol-
ecule conformation is directly correlated with its affinity to
the receptors and mechanism of action. It seems that even
a slight change in ligand structure affects the coactivator

























































Figure 6 The normalized concentration of IFN-γ (A) and IL-4
(B) produced by PBMNs after 24 and 48h of treatment with 30,
300 and 3000 ng/ml of aglepristone. All data are presented
relative to control values (line). Each point represents an individual
dog (N = 7–8), with the bar indicating the mean. *P < 0.05,

































































Figure 4 The percentage of IL-4-synthesizing T cell subsets
(A) and the MFI of IL-4-positive T cell subsets (B) treated for 24
and 48 h with 30, 300 and 3000 ng/ml of aglepristone. All data
are presented relative to control values (line). Each point represents
an individual dog (N = 7–8), with the bar indicating the mean.
*P < 0.05, ** P < 0.01.
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ture. For example, structure of conservative amino acid
motif in canine nPR vary from that in human nPR [36].
Mifepristone also shows different affinity to receptors































Figure 5 The production of IFN-γ and IL-4 by ConA- or PHA-
activated control PBMCs at 24 and 48 h of culture. Each point
represents an individual dog (N = 7), with the bar indicating the
mean. *P < 0.05, ** P < 0.01.Conclusions
In summary, our results demonstrated no effect of agle-
pristone on the synthesis of IFN-γ and IL-4 by resting or
mitogen-activated T cells of peripheral blood of canine
bitches in the luteal phase. Future studies are clearly
needed to evaluate the influence of aglepristone on pro-
liferation of mitogen-activated canine T cells. Obtained
results will help to understand the immunomodulatory
effect of antiprogestins on functional properties of ca-
nine immune cells.
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